Immunovant, Inc.
Immunovant, Inc. (IMVT): 7 pipeline candidates · 2 upcoming catalysts · 14 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
N/A
D/E 0.12 · 0% dilution
Lead: Phase 3
7 candidates
2 upcoming, next in ~228d
0 buys · 22 sells (180d)
A transparent, data-derived signal for Immunovant, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.9B
Cash
$902.1M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| Batoclimab | Phase 3 |
| Batoclimab 340 mg SC bi-weekly | Phase 3 |
| Batoclimab 340 mg SC weekly | Phase 3 |
| Batoclimab 680 mg SC weekly | Phase 3 |
| imeroprubart | Phase 2 |
| IMVT-1401 | Phase 2 |
| IMVT-1402 | Phase 2 |
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$2.79B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,947,888 | $421.0M |
| deep track capital, lp | 11,526,971 | $286.3M |
| vanguard capital management llc | 7,240,100 | $179.8M |
| blackrock, inc. | 6,574,497 | $163.3M |
| armistice capital, llc | 5,464,916 | $135.7M |
| baker bros. advisors lp | 5,457,881 | $135.6M |
| state street corp | 4,537,929 | $112.7M |
| woodline partners lp | 3,951,738 | $98.2M |
| morgan stanley | 3,876,877 | $96.3M |
| vanguard portfolio management llc | 3,704,905 | $92.0M |
Showing top 10 of 215 institutional holders of Immunovant, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immunovant, Inc.'s pipeline?
Immunovant, Inc. (IMVT) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immunovant, Inc.'s lead drug candidate?
Immunovant, Inc.'s most advanced tracked candidate is Batoclimab (Phase 3) for Thyroid Eye Disease; Chronic Inflammatory Demyelinating Polyneuropathy.
What is Immunovant, Inc.'s next catalyst?
Immunovant, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficac" — expected February 1, 2027.
What is Immunovant, Inc.'s market capitalization?
Immunovant, Inc.'s market capitalization is approximately $6.9B.
Who is the CEO of Immunovant, Inc.?
Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant, Inc. (IMVT).
Get the full picture on Immunovant, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.